Rocket Pharmaceuticals, Inc. (RCKT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Rocket Pharmaceuticals reported revenue of $0. Net income was -$223.1M, or -$2.01 per diluted share. Operating activities generated -$190.0M of cash, leaving -$190.5M of free cash flow. At fiscal year end, Rocket Pharmaceuticals held $330.4M in total assets against $53.2M in total liabilities, including $77.6M of cash and equivalents.
Open the full interactive Rocket Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Rocket Pharmaceuticals Key Stats
| Share Price | $2.30 |
|---|---|
| Market Cap | $263.4M |
| 52-Week Range | $2.30 – $5.30 |
| Shares Outstanding | 112.8 million (basic, 2026 Q2) |
Rocket Pharmaceuticals Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$134.3M | -$167.2M | -$224.3M | -$259.7M | -$273.2M | -$231.7M |
| Pre-Tax Income | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Income Tax | — | — | — | $0 | — | $0 |
| Net Income | -$139.7M | -$169.1M | -$221.9M | -$245.6M | -$258.7M | -$223.1M |
| Diluted EPS | -$2.52 | -$2.67 | -$3.26 | -$2.92 | -$2.73 | -$2.01 |
Rocket Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$50.3M | -$42.5M | -$47.6M | $123.2M |
| Diluted EPS | -$0.45 | -$0.38 | -$0.42 | $1.08 |
Rocket Pharmaceuticals Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $297.1M | $232.7M | $140.5M | $55.9M | $163.6M | $77.6M |
| Current Assets | $487.3M | $392.1M | $364.1M | $378.2M | $378.2M | $192.7M |
| Total Assets | $590.8M | $497.0M | $551.8M | $566.3M | $527.7M | $330.4M |
| Current Liabilities | $32.6M | $22.2M | $39.2M | $48.5M | $40.7M | $30.2M |
| Total Long-Term Debt | $39.9M | — | — | — | — | — |
| Total Liabilities | $87.3M | $42.3M | $62.1M | $73.8M | $64.5M | $53.2M |
| Shareholders' Equity | $503.5M | $454.7M | $489.7M | $492.6M | $463.2M | $277.2M |
Rocket Pharmaceuticals Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$74.6M | -$121.2M | -$178.1M | -$194.9M | -$209.7M | -$190.0M |
| Cash From Investing | -$96.6M | $18.9M | -$69.3M | -$98.1M | $131.7M | $103.8M |
| Cash From Financing | $283.0M | $37.7M | $155.3M | $208.4M | $185.7M | $148,000 |
| Free Cash Flow | -$95.2M | -$128.8M | -$186.5M | -$211.4M | -$215.6M | -$190.5M |
Figures from Rocket Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Rocket Pharmaceuticals financials page for every line item.
Rocket Pharmaceuticals Company Profile
| Ticker | RCKT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001281895 |
Frequently Asked Questions
What was Rocket Pharmaceuticals' revenue in fiscal 2025?
Rocket Pharmaceuticals (RCKT) reported revenue of $0 for fiscal 2025.
What is Rocket Pharmaceuticals' annual revenue history?
Rocket Pharmaceuticals' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Rocket Pharmaceuticals' net income in fiscal 2025?
Rocket Pharmaceuticals reported net income of -$223.1M for fiscal 2025.
What was Rocket Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Rocket Pharmaceuticals' diluted EPS was -$2.01 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Rocket Pharmaceuticals generate in fiscal 2025?
Rocket Pharmaceuticals generated -$190.5M of free cash flow in fiscal 2025.
What was Rocket Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Rocket Pharmaceuticals reported revenue of $0.
How many shares of Rocket Pharmaceuticals are outstanding?
Rocket Pharmaceuticals reported a weighted average of 112.8 million basic shares outstanding in 2026 Q2.
What is Rocket Pharmaceuticals' market cap?
Based on its latest closing price, Rocket Pharmaceuticals (RCKT) has a market capitalization of about $263.4M.
When does Rocket Pharmaceuticals' fiscal year end?
Rocket Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Rocket Pharmaceuticals headquartered?
Rocket Pharmaceuticals lists its business address in New York, New York in its SEC filings.